Top

BMC Cancer

Published in:

Open Access 01-12-2023 | Diffuse Large B-Cell Lymphoma | Research

An integrative bioinformatics investigation and experimental validation of chromobox family in diffuse large B-cell lymphoma

Authors: Fenling Zhou, Lu Chen, Peng Lu, Yuli Cao, Cuilan Deng, Gexiu Liu

Published in: BMC Cancer | Issue 1/2023

Abstract

Background

Diffuse large B-cell lymphoma (DLBCL) is one of the most aggressive malignant tumors. Chromobox (CBX) family plays the role of oncogenes in various malignancies.

Methods

The transcriptional and protein levels of CBX family were confirmed by GEPIA, Oncomine, CCLE, and HPA database. Screening of co-expressed genes and gene function enrichment analysis were performed by GeneMANIA and DAVID 6.8. The prognostic value, immune cell infiltration and drug sensitivity analysis of CBX family in DLBCL were performed by Genomicscape, TIMER2.0, and GSCALite database. Confirmatory Tests of CBX family protein expression in DLBCL were performed by immunohistochemistry.

Results

The mRNA and protein expressions of CBX1/2/3/5/6 were higher in DLBCL tissues than control groups. Enrichment analysis showed that the functions of CBX family were mainly related to chromatin remodeling, methylation-dependent protein binding, and VEGF signaling pathway. The high mRNA expressions of CBX2/3/5/6 were identified to be associated with short overall survival (OS) in DLBCL patients. Multivariate COX regression indicated that CBX3 was independent prognostic marker. Immune infiltration analysis revealed that the mRNA expressions of CBX family (especially CBX1, CBX5, and CBX6) in DLBCL were significantly correlated with the infiltration of most immune cells (including B cells, CD8 + T cells, CD4 + T cells, neutrophils, monocytes, macrophages, and Treg cells). Meanwhile, there was a strong correlation between the expression levels of CBX1/5/6 and surface markers of immune cells, such as the widely studied PVR-like protein receptor/ligand and PDL-1 immune checkpoint. Notably, our study found that DLBCL cells with CBX1 over-expression were resistant to the common anti-tumor drugs, but CBX2/5 had two polarities. Finally, we confirmed the higher expressions of CBX1/2/3/5/6 in DLBCL tissues compared with control groups by immunohistochemistry.

Conclusion

We provided a detailed analysis of the relationship between the CBX family and the prognosis of DLBCL. Distinguished from other studies, We found that high mRNA expressions of CBX2/3/5/6 were associated with poor prognosis in DLBCL patients, and Multivariate COX regression indicated that CBX3 was independent prognostic marker. Besides, our study also found an association between the CBX family and anti-tumour drug resistance, and provided a relationship between CBX family expression and immune cell infiltration.

Available only for authorised users

Menon MP, Pittaluga S, Jaffe ES. The histological and biological spectrum of diffuse large B-cell lymphoma in the World Health Organization classification. Cancer J. 2012;18(5):411–20. https://doi.org/10.1097/PPO.0b013e31826aee97.CrossRefPubMedPubMedCentral

Zhang J, Grubor V, Love CL, Banerjee A, Richards KL, Mieczkowski PA, Dunphy C, Choi W, Au WY, Srivastava G, et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A. 2013;110(4):1398–403. https://doi.org/10.1073/pnas.1205299110.CrossRefPubMedPubMedCentral

Younes A. Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin: Seeing the Forest and the Trees. J Clin Oncol. 2015;33(26):2835–6. https://doi.org/10.1200/jco.2015.61.9288.CrossRefPubMed

Reddy NM, Thieblemont C. Maintenance therapy following induction chemoimmunotherapy in patients with diffuse large B-cell lymphoma: current perspective. Ann Oncol. 2017;28(11):2680–90. https://doi.org/10.1093/annonc/mdx358.CrossRefPubMed

Klemm F, Joyce JA. Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol. 2015;25(4):198–213. https://doi.org/10.1016/j.tcb.2014.11.006.CrossRefPubMed

Ma RG, Zhang Y, Sun TT, Cheng B. Epigenetic regulation by polycomb group complexes: focus on roles of CBX proteins. J Zhejiang Univ Sci B. 2014;15(5):412–28. https://doi.org/10.1631/jzus.B1400077.CrossRefPubMedPubMedCentral

Ning G, Huang YL, Zhen LM, Xu WX, Jiao Q, Yang FJ, Wu LN, Zheng YY, Song J, Wang YS, et al. Transcriptional expressions of Chromobox 1/2/3/6/8 as independent indicators for survivals in hepatocellular carcinoma patients. Aging. 2018;10(11):3450–73. https://doi.org/10.18632/aging.101658.CrossRefPubMedPubMedCentral

Zeng JS, Zhang ZD, Pei L, Bai ZZ, Yang Y, Yang H, Tian QH. CBX4 exhibits oncogenic activities in breast cancer via Notch1 signaling. Int J Biochem Cell Biol. 2018;95:1–8. https://doi.org/10.1016/j.biocel.2017.12.006.CrossRefPubMed

Alam H, Li N, Dhar SS, Wu SJ, Lv J, Chen K, Flores ER, Baseler L, Lee MG. HP1γ Promotes Lung Adenocarcinoma by Downregulating the Transcription-Repressive Regulators NCOR2 and ZBTB7A. Can Res. 2018;78(14):3834–48. https://doi.org/10.1158/0008-5472.Can-17-3571.CrossRef

10.

Hu C, Zhang Q, Tang Q, Zhou H, Liu W, Huang J, Liu Y, Wang Q, Zhang J, Zhou M, et al. CBX4 promotes the proliferation and metastasis via regulating BMI-1 in lung cancer. J Cell Mol Med. 2020;24(1):618–31. https://doi.org/10.1111/jcmm.14771.CrossRefPubMed

11.

Yu YH, Chiou GY, Huang PI, Lo WL, Wang CY, Lu KH, Yu CC, Alterovitz G, Huang WC, Lo JF, et al. Network biology of tumor stem-like cells identified a regulatory role of CBX5 in lung cancer. Sci Rep. 2012;2:584. https://doi.org/10.1038/srep00584.CrossRefPubMedPubMedCentral

12.

Liu Y, Wang J, Li L, Qin H, Wei Y, Zhang X, Ren X, Ding W, Shen X, Li G et al: AC010973.2 promotes cell proliferation and is one of six stemness-related genes that predict overall survival of renal clear cell carcinoma. Sci Rep. 2022;12(1):4272. https://doi.org/10.1038/s41598-022-07070-1.

13.

Jiang S, Ren X, Liu S, Lu Z, Xu A, Qin C, Wang Z: Integrated Analysis of the Prognosis-Associated RNA-Binding Protein Genes and Candidate Drugs in Renal Papillary Cell Carcinoma. Front Genetics. 2021;12:627508. https://doi.org/10.3389/fgene.2021.627508.

14.

Zhang D, Xu X, Wei Y, Chen X, Li G, Lu Z, Zhang X, Ren X, Wang S, Qin C. Prognostic Role of DNA Damage Response Genes Mutations and their Association With the Sensitivity of Olaparib in Prostate Cancer Patients. Cancer Control. 2022;29:10732748221129452. https://doi.org/10.1177/10732748221129451.CrossRefPubMedPubMedCentral

15.

Yu L, Shen H, Ren X, Wang A, Zhu S, Zheng Y, Wang X. Multi-omics analysis reveals the interaction between the complement system and the coagulation cascade in the development of endometriosis. Sci Rep. 2021;11(1):11926. https://doi.org/10.1038/s41598-021-90112-x.CrossRefPubMedPubMedCentral

16.

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–102. https://doi.org/10.1093/nar/gkx247.CrossRefPubMedPubMedCentral

17.

Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ, Kincead-Beal C, Kulkarni P et al: Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 2007;9(2):166–180. https://doi.org/10.1593/neo.07112.

18.

Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehar J, Kryukov GV, Sonkin D, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483(7391):603–7. https://doi.org/10.1038/nature11003.CrossRefPubMedPubMedCentral

19.

Li W, Cowley A, Uludag M, Gur T, McWilliam H, Squizzato S, Park YM, Buso N, Lopez R. The EMBL-EBI bioinformatics web and programmatic tools framework. Nucleic Acids Res. 2015;43(W1):W580-584. https://doi.org/10.1093/nar/gkv279.CrossRefPubMedPubMedCentral

20.

Warde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, Chao P, Franz M, Grouios C, Kazi F, Lopes CT et al: The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res. 2010;38(Web Server issue):W214–220. https://doi.org/10.1093/nar/gkq537.

21.

da Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44–57. https://doi.org/10.1038/nprot.2008.211.CrossRefPubMed

22.

Asplund A, Edqvist PH, Schwenk JM, Pontén F. Antibodies for profiling the human proteome-The Human Protein Atlas as a resource for cancer research. Proteomics. 2012;12(13):2067–77. https://doi.org/10.1002/pmic.201100504.CrossRefPubMed

23.

Kassambara A, Rème T, Jourdan M, Fest T, Hose D, Tarte K, Klein B: GenomicScape: an easy-to-use web tool for gene expression data analysis. Application to investigate the molecular events in the differentiation of B cells into plasma cells. PLoS Comput Biol. 2015;11(1):e1004077. https://doi.org/10.1371/journal.pcbi.1004077.

24.

Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, Li B, Liu XS: TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48(W1):W509-w514. https://doi.org/10.1093/nar/gkaa407.

25.

Liu CJ, Hu FF, Xia MX, Han L, Zhang Q, Guo AY. GSCALite: a web server for gene set cancer analysis. Bioinformatics (Oxford, England). 2018;34(21):3771–2. https://doi.org/10.1093/bioinformatics/bty411.CrossRefPubMed

26.

Basso K, Margolin AA, Stolovitzky G, Klein U, Dalla-Favera R, Califano A. Reverse engineering of regulatory networks in human B cells. Nat Genet. 2005;37(4):382–90. https://doi.org/10.1038/ng1532.CrossRefPubMed

27.

Brune V, Tiacci E, Pfeil I, Döring C, Eckerle S, van Noesel CJ, Klapper W, Falini B, von Heydebreck A, Metzler D, et al. Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. J Exp Med. 2008;205(10):2251–68. https://doi.org/10.1084/jem.20080809.CrossRefPubMedPubMedCentral

28.

Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q, Bertoni F, Ponzoni M, Scandurra M, Califano A, et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature. 2009;459(7247):717–21. https://doi.org/10.1038/nature07968.CrossRefPubMedPubMedCentral

29.

Storz MN, van de Rijn M, Kim YH, Mraz-Gernhard S, Hoppe RT, Kohler S. Gene expression profiles of cutaneous B cell lymphoma. J Invest Dermatol. 2003;120(5):865–70. https://doi.org/10.1046/j.1523-1747.2003.12142.x.CrossRefPubMed

30.

Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27–30. https://doi.org/10.1093/nar/28.1.27.CrossRefPubMedPubMedCentral

31.

Kanehisa M. Toward understanding the origin and evolution of cellular organisms. Protein science : a publication of the Protein Society. 2019;28(11):1947–51. https://doi.org/10.1002/pro.3715.CrossRefPubMed

32.

Kanehisa M, Furumichi M, Sato Y, Kawashima M, Ishiguro-Watanabe M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2023;51(D1):D587-d592. https://doi.org/10.1093/nar/gkac963.CrossRefPubMed

33.

Azimi F, Scolyer RA, Rumcheva P, Moncrieff M, Murali R, McCarthy SW, Saw RP, Thompson JF. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol. 2012;30(21):2678–83. https://doi.org/10.1200/jco.2011.37.8539.CrossRefPubMed

34.

Ohtani H. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer. Cancer Immun. 2007;7:4.PubMedPubMedCentral

35.

Ravelli A, Roviello G, Cretella D, Cavazzoni A, Biondi A, Cappelletti MR, Zanotti L, Ferrero G, Ungari M, Zanconati F, et al. Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility. Tumour Biol. 2017;39(4):1010428317695023. https://doi.org/10.1177/1010428317695023.CrossRefPubMed

36.

Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90. https://doi.org/10.1182/blood-2016-01-643569.CrossRefPubMedPubMedCentral

37.

Gil J, O’Loghlen A. PRC1 complex diversity: where is it taking us? Trends Cell Biol. 2014;24(11):632–41. https://doi.org/10.1016/j.tcb.2014.06.005.CrossRefPubMed

38.

Huang Y, Lin Y, Song X, Wu D. LINC00857 contributes to proliferation and lymphomagenesis by regulating miR-370-3p/CBX3 axis in diffuse large B-cell lymphoma. Carcinogenesis. 2021;42(5):733–41. https://doi.org/10.1093/carcin/bgab013.CrossRefPubMed

39.

Del Gaudio N, Di Costanzo A, Liu NQ, Conte L, Dell’Aversana C, Bove G, Benedetti R, Montella L, Ciardiello F, Carafa V, et al. CBX2 shapes chromatin accessibility promoting AML via p38 MAPK signaling pathway. Mol Cancer. 2022;21(1):125. https://doi.org/10.1186/s12943-022-01603-y.CrossRefPubMedPubMedCentral

40.

Yang YF, Pan YH, Tian QH, Wu DC, Su SG. CBX1 Indicates Poor Outcomes and Exerts Oncogenic Activity in Hepatocellular Carcinoma. Transl Oncol. 2018;11(5):1110–8. https://doi.org/10.1016/j.tranon.2018.07.002.CrossRefPubMedPubMedCentral

41.

Zhu Y, Pu Z, Li Z, Lin Y, Li N, Peng F: Comprehensive Analysis of the Expression and Prognosis Value of Chromobox Family Members in Clear Cell Renal Cell Carcinoma. Front Oncol. 2021;11:700528. https://doi.org/10.3389/fonc.2021.700528.

42.

Zhou H, Xiong Y, Liu Z, Hou S, Zhou T. Expression and prognostic significance of CBX2 in colorectal cancer: database mining for CBX family members in malignancies and vitro analyses. Cancer Cell Int. 2021;21(1):402. https://doi.org/10.1186/s12935-021-02106-4.CrossRefPubMedPubMedCentral

43.

Slezak J, Truong M, Huang W, Jarrard D. HP1γ expression is elevated in prostate cancer and is superior to Gleason score as a predictor of biochemical recurrence after radical prostatectomy. BMC Cancer. 2013;13:148. https://doi.org/10.1186/1471-2407-13-148.CrossRefPubMedPubMedCentral

44.

Wang RB, Li YC, Zhou Q, Lv SZ, Yuan KY, Wu JP, Zhao YJ, Song QK, Zhu B. Overexpression of CD155 is associated with PD-1 and PD-L1 expression on immune cells, rather than tumor cells in the breast cancer microenvironment. World J Clin Cases. 2020;8(23):5935–43. https://doi.org/10.12998/wjcc.v8.i23.5935.CrossRefPubMedPubMedCentral

45.

Sun J, Zhang Z, Bao S, Yan C, Hou P, Wu N, Su J, Xu L, Zhou M: Identification of tumor immune infiltration-associated lncRNAs for improving prognosis and immunotherapy response of patients with non-small cell lung cancer. J Immunother Cancer. 2020;8(1). https://doi.org/10.1136/jitc-2019-000110.

46.

Zhou M, Zhang Z, Bao S, Hou P, Yan C, Su J, Sun J: Computational recognition of lncRNA signature of tumor-infiltrating B lymphocytes with potential implications in prognosis and immunotherapy of bladder cancer. Brief Bioinform. 2021; 22(3). https://doi.org/10.1093/bib/bbaa047.

47.

Chan CJ, Andrews DM, Smyth MJ. Receptors that interact with nectin and nectin-like proteins in the immunosurveillance and immunotherapy of cancer. Curr Opin Immunol. 2012;24(2):246–51. https://doi.org/10.1016/j.coi.2012.01.009.CrossRefPubMed

48.

Jin H-s. Park Y: Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy. BMB Rep. 2021;54(1):2–11. https://doi.org/10.5483/BMBRep.2021.54.1.229.CrossRefPubMedPubMedCentral

49.

Sanchez-Correa B, Valhondo I, Hassouneh F, Lopez-Sejas N, Pera A, Bergua JM, Arcos MJ, Bañas H, Casas-Avilés I, Durán E et al: DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy. Cancers. 2019;11(6). https://doi.org/10.3390/cancers11060877.

50.

Wu B, Zhong C, Lang Q, Liang Z, Zhang Y, Zhao X, Yu Y, Zhang H, Xu F, Tian Y. Poliovirus receptor (PVR)-like protein cosignaling network: new opportunities for cancer immunotherapy. J Exp Clin Cancer Res. 2021;40(1):267. https://doi.org/10.1186/s13046-021-02068-5.CrossRefPubMedPubMedCentral

51.

Daassi D, Mahoney KM, Freeman GJ. The importance of exosomal PDL1 in tumour immune evasion. Nat Rev Immunol. 2020;20(4):209–15. https://doi.org/10.1038/s41577-019-0264-y.CrossRefPubMed

52.

Zhao L, Liu Y, Zhang J, Liu Y, Qi Q. LncRNA SNHG14/miR-5590-3p/ZEB1 positive feedback loop promoted diffuse large B cell lymphoma progression and immune evasion through regulating PD-1/PD-L1 checkpoint. Cell Death Dis. 2019;10(10):731. https://doi.org/10.1038/s41419-019-1886-5.CrossRefPubMedPubMedCentral

53.

Zhao W, Ma B, Tian Z, Han H, Tang J, Dong B, An G, Cao B, Wang B. Inhibiting CBX4 efficiently protects hepatocellular carcinoma cells against sorafenib resistance. Br J Cancer. 2021;124(7):1237–48. https://doi.org/10.1038/s41416-020-01240-6.CrossRefPubMedPubMedCentral

Title: An integrative bioinformatics investigation and experimental validation of chromobox family in diffuse large B-cell lymphoma
Authors: Fenling Zhou
Lu Chen
Peng Lu
Yuli Cao
Cuilan Deng
Gexiu Liu
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Published in: BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-023-11108-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2023

Comprehensive transcriptomic analyses identify KDM genes-related subtypes with different TME infiltrates in gastric cancer

First-line atezolizumab/durvalumab plus platinum–etoposide combined with radiotherapy in extensive-stage small-cell lung cancer

Somatic mutation landscape in a cohort of meningiomas that have undergone grade progression

Global burden of prostate cancer attributable to smoking among males in 204 countries and territories, 1990–2019

Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy with or without nimotuzumab in the treatment of locally advanced nasopharyngeal carcinoma: a retrospective study

Chemotherapy and targeted therapy for advanced biliary tract cancers: an umbrella review

Keynote webinar | Spotlight on antibody–drug conjugates in cancer